190 related articles for article (PubMed ID: 31036409)
1. Hutchinson-Gilford Progeria Syndrome: Cardiovascular Pathologies and Potential Therapies.
Xu S; Jin ZG
Trends Biochem Sci; 2019 Jul; 44(7):561-564. PubMed ID: 31036409
[TBL] [Abstract][Full Text] [Related]
2. Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome.
Gordon LB; Massaro J; D'Agostino RB; Campbell SE; Brazier J; Brown WT; Kleinman ME; Kieran MW;
Circulation; 2014 Jul; 130(1):27-34. PubMed ID: 24795390
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular pathology in Hutchinson-Gilford progeria: correlation with the vascular pathology of aging.
Olive M; Harten I; Mitchell R; Beers JK; Djabali K; Cao K; Erdos MR; Blair C; Funke B; Smoot L; Gerhard-Herman M; Machan JT; Kutys R; Virmani R; Collins FS; Wight TN; Nabel EG; Gordon LB
Arterioscler Thromb Vasc Biol; 2010 Nov; 30(11):2301-9. PubMed ID: 20798379
[TBL] [Abstract][Full Text] [Related]
4. Hutchinson-Gilford progeria syndrome.
Ullrich NJ; Gordon LB
Handb Clin Neurol; 2015; 132():249-64. PubMed ID: 26564085
[TBL] [Abstract][Full Text] [Related]
5. Neurologic features of Hutchinson-Gilford progeria syndrome after lonafarnib treatment.
Ullrich NJ; Kieran MW; Miller DT; Gordon LB; Cho YJ; Silvera VM; Giobbie-Hurder A; Neuberg D; Kleinman ME
Neurology; 2013 Jul; 81(5):427-30. PubMed ID: 23897869
[TBL] [Abstract][Full Text] [Related]
6. Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome.
Gordon LB; Kleinman ME; Miller DT; Neuberg DS; Giobbie-Hurder A; Gerhard-Herman M; Smoot LB; Gordon CM; Cleveland R; Snyder BD; Fligor B; Bishop WR; Statkevich P; Regen A; Sonis A; Riley S; Ploski C; Correia A; Quinn N; Ullrich NJ; Nazarian A; Liang MG; Huh SY; Schwartzman A; Kieran MW
Proc Natl Acad Sci U S A; 2012 Oct; 109(41):16666-71. PubMed ID: 23012407
[TBL] [Abstract][Full Text] [Related]
7. Plasma Progerin in Patients With Hutchinson-Gilford Progeria Syndrome: Immunoassay Development and Clinical Evaluation.
Gordon LB; Norris W; Hamren S; Goodson R; LeClair J; Massaro J; Lyass A; D'Agostino RB; Tuminelli K; Kieran MW; Kleinman ME
Circulation; 2023 Jun; 147(23):1734-1744. PubMed ID: 36919608
[TBL] [Abstract][Full Text] [Related]
8. Clinical Trial of the Protein Farnesylation Inhibitors Lonafarnib, Pravastatin, and Zoledronic Acid in Children With Hutchinson-Gilford Progeria Syndrome.
Gordon LB; Kleinman ME; Massaro J; D'Agostino RB; Shappell H; Gerhard-Herman M; Smoot LB; Gordon CM; Cleveland RH; Nazarian A; Snyder BD; Ullrich NJ; Silvera VM; Liang MG; Quinn N; Miller DT; Huh SY; Dowton AA; Littlefield K; Greer MM; Kieran MW
Circulation; 2016 Jul; 134(2):114-25. PubMed ID: 27400896
[TBL] [Abstract][Full Text] [Related]
9. Extraskeletal Calcifications in Hutchinson-Gilford Progeria Syndrome.
Gordon CM; Cleveland RH; Baltrusaitis K; Massaro J; D'Agostino RB; Liang MG; Snyder B; Walters M; Li X; Braddock DT; Kleinman ME; Kieran MW; Gordon LB
Bone; 2019 Aug; 125():103-111. PubMed ID: 31077852
[TBL] [Abstract][Full Text] [Related]
10. An overview of treatment strategies for Hutchinson-Gilford Progeria syndrome.
Harhouri K; Frankel D; Bartoli C; Roll P; De Sandre-Giovannoli A; Lévy N
Nucleus; 2018 Jan; 9(1):246-257. PubMed ID: 29619863
[TBL] [Abstract][Full Text] [Related]
11. Molecular and Cellular Mechanisms Driving Cardiovascular Disease in Hutchinson-Gilford Progeria Syndrome: Lessons Learned from Animal Models.
Benedicto I; Dorado B; Andrés V
Cells; 2021 May; 10(5):. PubMed ID: 34064612
[TBL] [Abstract][Full Text] [Related]
12. Moving from gene discovery to clinical trials in Hutchinson-Gilford progeria syndrome.
King AA; Heyer GL
Neurology; 2013 Jul; 81(5):408-9. PubMed ID: 23897868
[No Abstract] [Full Text] [Related]
13. Hutchinson-Gilford progeria syndrome: Cardiovascular manifestations and treatment.
Lian J; Du L; Li Y; Yin Y; Yu L; Wang S; Ma H
Mech Ageing Dev; 2023 Dec; 216():111879. PubMed ID: 37832833
[TBL] [Abstract][Full Text] [Related]
14. Hutchinson-Gilford Progeria Syndrome: A Premature Aging Disease.
Ahmed MS; Ikram S; Bibi N; Mir A
Mol Neurobiol; 2018 May; 55(5):4417-4427. PubMed ID: 28660486
[TBL] [Abstract][Full Text] [Related]
15. Association of Lonafarnib Treatment vs No Treatment With Mortality Rate in Patients With Hutchinson-Gilford Progeria Syndrome.
Gordon LB; Shappell H; Massaro J; D'Agostino RB; Brazier J; Campbell SE; Kleinman ME; Kieran MW
JAMA; 2018 Apr; 319(16):1687-1695. PubMed ID: 29710166
[TBL] [Abstract][Full Text] [Related]
16. FDA approval summary for lonafarnib (Zokinvy) for the treatment of Hutchinson-Gilford progeria syndrome and processing-deficient progeroid laminopathies.
Suzuki M; Jeng LJB; Chefo S; Wang Y; Price D; Li X; Wang J; Li RJ; Ma L; Yang Y; Zhang X; Zheng N; Zhang K; Joseph DB; Shroff H; Doan J; Pacanowski M; Smpokou P; Donohue K; Joffe HV
Genet Med; 2023 Feb; 25(2):100335. PubMed ID: 36507973
[TBL] [Abstract][Full Text] [Related]
17. Hutchinson-Gilford progeria syndrome, cardiovascular disease and oxidative stress.
Trigueros-Motos L; Gonzalez JM; Rivera J; Andres V
Front Biosci (Schol Ed); 2011 Jun; 3(4):1285-97. PubMed ID: 21622271
[TBL] [Abstract][Full Text] [Related]
18. Progeria: a rare genetic premature ageing disorder.
Sinha JK; Ghosh S; Raghunath M
Indian J Med Res; 2014 May; 139(5):667-74. PubMed ID: 25027075
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of vascular aging: What can we learn from Hutchinson-Gilford progeria syndrome?
Del Campo L; Hamczyk MR; Andrés V; Martínez-González J; Rodríguez C;
Clin Investig Arterioscler; 2018; 30(3):120-132. PubMed ID: 29602596
[TBL] [Abstract][Full Text] [Related]
20. Vascular smooth muscle cell loss underpins the accelerated atherosclerosis in Hutchinson-Gilford progeria syndrome.
Hamczyk MR; Andrés V
Nucleus; 2019 Dec; 10(1):28-34. PubMed ID: 30900948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
